Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

Phase 1

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: PF-06700841 tablet
Other: Placebo
Drug: PF-06700841 oral solution/suspension

First Posted Date: 2014-12-08

Last Posted Date: 2017-03-08

Lead Sponsor: Pfizer

Target Recruit Count: 96

Registration Number: NCT02310750

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

POC Study in Partially Responsive Generalized Anxiety Disorder

Phase 2

Terminated

Conditions: Generalized Anxiety Disorder

Interventions: Drug: PF-06372865.

First Posted Date: 2014-12-08

Last Posted Date: 2017-01-09

Lead Sponsor: Pfizer

Target Recruit Count: 90

Registration Number: NCT02310568

Locations: 🇺🇸
Gulfcoast Clinical Center, Fort Meyers, Florida, United States
🇺🇸
Sun Valley Research Center, Imperial, California, United States
🇺🇸
Pharmacology Research Institute, Encino, California, United States

and more 40 locations

Safety and Pharmacokinetic Study of PF-06651600 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06651600 or Placebo

First Posted Date: 2014-12-05

Last Posted Date: 2016-09-19

Lead Sponsor: Pfizer

Target Recruit Count: 80

Registration Number: NCT02309827

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

Phase 1

Terminated

Conditions: Healthy

Interventions: Other: Placebo
Drug: PF-06412562 3mg BID
Drug: PF-06412562 15mg BID

First Posted Date: 2014-12-03

Last Posted Date: 2017-08-17

Lead Sponsor: Pfizer

Target Recruit Count: 77

Registration Number: NCT02306876

Locations: 🇺🇸
Arcadia MRI & Imaging Center, Arcadia, California, United States
🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
🇺🇸
Glendale Adventist Medical Center, Glendale, California, United States

Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa

Completed

Conditions: Non-small Cell Lung Cancer

First Posted Date: 2014-12-02

Last Posted Date: 2019-07-19

Lead Sponsor: Pfizer

Target Recruit Count: 449

Registration Number: NCT02304406

Locations: 🇲🇦
Institut National d'Oncologie, Rabat, Morocco
🇪🇬
National Cancer Institute, Cairo, Egypt
🇱🇧
American University in Beirut, Beirut, Lebanon

and more 6 locations

A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations

Phase 2

Terminated

Conditions: Triple Negative Breast Neoplasms

Interventions: Drug: PF-03084014

First Posted Date: 2014-11-24

Last Posted Date: 2019-01-08

Lead Sponsor: Pfizer

Target Recruit Count: 19

Registration Number: NCT02299635

Locations: 🇺🇸
Brigham and Women's Hospital (BWH), Boston, Massachusetts, United States
🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States

and more 32 locations

A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

Phase 2

Withdrawn

Conditions: Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC

Interventions: Drug: PF-06459988

First Posted Date: 2014-11-21

Last Posted Date: 2015-01-12

Lead Sponsor: Pfizer

Registration Number: NCT02297425

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

Phase 3

Active, not recruiting

Conditions: Breast Neoplasms

Interventions: Drug: Placebo
Drug: Palbociclib
Drug: Letrozole

First Posted Date: 2014-11-21

Last Posted Date: 2024-10-21

Lead Sponsor: Pfizer

Target Recruit Count: 340

Registration Number: NCT02297438

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳
The Tumor Hospital of Yunnan Province, Kunming, Yunnan, China
🇨🇳
The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

and more 51 locations

Actual Use Trial of Ibuprofen 400 mg

Phase 3

Completed

Conditions: Patient Compliance

Interventions: Drug: Ibuprofen 400 mg caplet

First Posted Date: 2014-11-19

Last Posted Date: 2016-05-30

Lead Sponsor: Pfizer

Target Recruit Count: 738

Registration Number: NCT02294019

Locations: 🇺🇸
Community Clinical Pharmacy, Mesa, Arizona, United States
🇺🇸
Family Plaza Pharmacy, West Jordan, Utah, United States
🇺🇸
Robert's Discount Pharmacy, Hoover, Alabama, United States

and more 19 locations

A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: PF-04937319 high dose
Drug: PF-04937319 low dose

First Posted Date: 2014-11-17

Last Posted Date: 2016-03-15

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT02292433

Locations: 🇯🇵
P-one Clinic, Keikokai Medical Corporation, Hachioji-shi, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy